Ajay Kuriyan, MD
Ophthalmology · Plymouth Meeting, PANPI 1760786982
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (33.2%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Alcon Research LLC at 33.4% of the total. Reporting peaked in 2022 at $99,839 and has fallen 83.4% since, to $16,585 in 2025. Among ophthalmology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 210 payments — averaging $1076.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$75K
- Genentech USA, Inc.$44K
- Bausch & Lomb Americas Inc.$28K
- Astellas Pharma US Inc$21K
- Spark Therapeutics, Inc.$15K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$11K
- plus $31K from 16 others
Across 11 payments — averaging $9018.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$67K
- AbbVie$27K
- F. Hoffmann-la Roche AG$5K
What the payments were for
- Consulting fees$68,70630%
- Speaking & faculty fees$59,07526%
- Grants$75,00033%
- Travel & lodging$17,4028%
- Food & beverage$5,8383%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 2 | $75,465 |
| Genentech USA, Inc. | 33 | $44,165 |
| Bausch & Lomb Americas Inc. | 49 | $27,789 |
| Astellas Pharma US Inc | 19 | $21,487 |
| Spark Therapeutics, Inc. | 12 | $15,269 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 14 | $10,867 |
| Alimera Sciences, Inc. | 8 | $7,621 |
| Genentech, Inc. | 7 | $7,383 |
| AbbVie(2 entities) | 5 | $4,285 |
| Novartis | 5 | $2,248 |
| Neurotech Pharmaceuticals, Inc. | 2 | $2,158 |
| Optos, Inc. | 1 | $2,000 |
| F. Hoffmann-la Roche AG | 1 | $1,680 |
| Eyepoint US, Inc. | 2 | $1,631 |
| Alcon | 7 | $849 |
| Boston Scientific | 31 | $639 |
| Regeneron Healthcare Solutions, Inc. | 3 | $190 |
| Carl Zeiss Meditec, Inc. | 3 | $182 |
| Biotissue Holdings Inc. | 3 | $55 |
| Regeneron | 1 | $36 |
| Rayner Intraocular Lenses Limited | 1 | $31 |
| Olympus Corporation Of The Americas | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$36,500
- Izervay$19,166
- Lucentis$17,217
- STELLARIS ELITE$10,582
- STELLARIS$9,666
- STELLARIS PC$9,390
- LIGHT PIPES$9,390
- OPHTHALMIC INSTRUMENTS$9,390
- VITESSE$9,390
- SURGICAL MISC$9,262
- Iluvien$7,400
- LUXTURNA$6,825
- OZURDEX$4,145
- SUSVIMO$2,520
- BEOVU$2,098
- P200DTx$2,000
- YUTIQ$1,620
- Constellation$153
- EYLEA HD$128
- WaveWriter Alpha Prime 16$123
How this compares
$226,048 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 390 | $21,505 |
| ProlensaBromfenac Sodium | 29 | $9,982 |
| Ketorolac Tromethamine | 305 | $6,958 |
| Bromfenac Sodium | 36 | $6,439 |
| Difluprednate | 44 | $4,748 |
| Atropine Sulfate | 35 | $1,434 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 58 | $1,103 |
| Dorzolamide Hcl | 81 | $1,100 |
| Ofloxacin | 36 | $606 |
| Timolol Maleate | 39 | $349 |
| Brimonidine Tartrate | 31 | $310 |
| Diclofenac Sodium | 23 | $293 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 21 | $177 |
| Latanoprost | 21 | $144 |
| ErythromycinErythromycin Base | 14 | $133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $10,867 | $9,98229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Plymouth Meeting
- Carl RegilloPlymouth Meeting$721K
- Michael KlufasPlymouth Meeting$393K
- Allen HoPlymouth Meeting$225K
- Sunir GargPlymouth Meeting$216K
- Yoshihiro YonekawaPlymouth Meeting$95K
- Omesh GuptaPlymouth Meeting$85K
- Sonia MehtaPlymouth Meeting$49K
- Julia HallerPhiladelphia$1.5M
- Francis MahPittsburgh$1.1M
- Brandon AyresBala Cynwyd$929K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.